When: Dip to 10 EMA ($150.55)/50 SMA ($151.42) confluence at $148-150

Then: Deploy ~33% of target position

When: Test of rising 200 SMA ($142.94) at $140-143 with positive MACD divergence or successful defense

Then: Deploy ~33-42% of target position

When: Confirmed close above $166 on volume >3M

Then: Rebuild trimmed position with stop at $155

HOLD-SIZE-WITH-OPTIONAL-SCALE-IN

• Three rejections at 163-166 represent distribution pattern, not base-building - supply consistently overwhelms demand at same level
• 33.7x trailing PE multiple faces compression risk from hawkish Fed regime with 61% probability of two more hikes in 2026
• 43% of total assets are goodwill creating tail risk; current ratio of 0.90 indicates operating cash flow dependency
• MACD negative at minus 0.78 with 10 EMA below 50 SMA indicates momentum only 30% through confirmation process
• Net debt to EBITDA around 1.8x against 13.2 billion total debt load is uncomfortable in cyclical downturn scenario
• Asymmetric payoff closer to 1-to-1 with fat left tail rather than 2-to-1 favorability
• Recommend 4% max position size with initial tranche at 25% of target rather than 33%
• Pre-commit to adding only on successful retest of 200 SMA around 143 or confirmed breakout above 163.50 on volume

→ vs aggressive: Distribution pattern at 163-166 is being reframed as base-building but supply has consistently overwhelmed demand three times; calling that accumulation is narrative construction destroyed by current data

→ vs aggressive: Priced in doesn't mean priced permanently; 61% probability of two more hikes means 40% chance path is even worse, and cyclicals reprice continuously as discount rates extend

→ vs aggressive: Net debt of 10.9 billion with 43% goodwill is not 'old news fully digested' - it represents refinancing and impairment risk when discount rates rise

→ vs aggressive: Upside to 170 assumes no multiple compression over 18 months; in hawkish regime with beta 1.23, realistic scenario is chop while rates work on multiple

→ vs neutral: Hold is too passive given fundamental quality; but hold-size-with-optional-scale-in is the disciplined version of buy that survives a 10% drawdown

→ vs neutral: Skipping 163.50 confirmation to 'buy the business ahead of the market' is rationalizing bad entry discipline; quality doesn't entitle investor to bad entry point

BUY at reduced size with disciplined three-tranche scale-in; total position capped at 4-5% portfolio

• Base case target is 160-165 over 12-18 months, not 170; 170 is the optimistic case requiring multiple to hold at 21x forward in hawkish regime
• True expected return is 4-7% over 12-18 months plus 3.5-4% shareholder yield, totaling 7-11% - not the 2-to-1 payoff the aggressive analyst claims
• Technical pattern is topping pattern inside structural uptrend, not pure accumulation; three rejections at 163-166 with falls to 130, 144, and another drop suggest real supply at resistance
• Fed is continuous headwind: 61% probability of two more hikes means multiple on 33.7x trailing PE could compress further; 200bp move in 10-year yields could push stock to 140
• Net debt to EBITDA at 1.8x being actively reduced toward 1.5x target in 18 months; balance sheet improving but 43% goodwill concentration and 0.90 current ratio are real bounded risks
• MACD momentum only 30-40% confirmed: histogram positive but line still negative, 10 EMA below 50 SMA
• AI capex super-cycle stall risk is real but bounded for EMR's diversified industrial customer base
• Downside probability to 130 is 15-20%; upside probability to 165+ is 35-40% over same window; asymmetry favors ownership at correct size
• Higher lows since September 2025 are real but not classic accumulation - more like stretched spring that's snapped back three times
• Waiting for 163.50 confirmation is not risk-free: failed breakout means 10-15% drawdown from chase point at 165+

→ vs aggressive: 170 target is optimistic case, not base case; true base case is 160-165 with 4-7% total return, making risk-reward approximately 1.3-to-1 not 2-to-1

→ vs aggressive: Three rejections at 163-166 followed by falls to 130, 144, and another drop is not accumulation - supply is real and unproven at that level

→ vs aggressive: MACD is only 30-40% confirmed; line still negative and EMA stack not in bullish order

→ vs conservative: Probability of falling to 130 is 15-20% (meaningful but not dominant), not high enough to justify sitting in cash for a quality compounder at 21x forward PE

→ vs conservative: Pure distribution patterns don't make higher highs and higher lows; we're in topping pattern inside structural uptrend, not pure distribution

→ vs conservative: 43% goodwill and 0.90 current ratio are real but bounded and improving risks, not reasons to prevent ownership